News
Fri, 06 Sep 2019 07:55:00 -0400
Fri, 06 Sep 2019 07:55:00 -0400
PLAINSBORO, N.J., Sept. 6, 2019 /PRNewswire/ -- Novo Nordisk is expanding the company's affordability offering in the US beginning January 2, 2020. People with diabetes experience different issues and complexities that can't be covered by one solution. That's why the company continues to bring forth programs that will directly benefit even more people with diabetes – including those with insurance and those without – as we work toward much needed longer-term systemic reform.
Expanded affordability options available on January 2, 2020
The new offerings will include:
Follow-On Brand (FOB) List Prices: |
||||
Insulin Aspart FOB 10mL vial/1000 Units: |
$144.68 |
|||
Insulin Aspart FOB 5x3mL Penfill® (box of 5 pens)/1500 Units: |
$268.73 |
|||
Insulin Aspart FOB 5x3mL FlexPen® (box of 5 pens)/1500 Units: |
$279.41 |
|||
Insulin Aspart Mix 70/30 FOB 10mL vial/1000 Units: |
$150.06 |
|||
Insulin Aspart Mix 70/30 FOB 5x3mL FlexPen® (box of 5 pens)/1500 Units: |
$279.41 |
NovoLog® and NovoLog® Mix will still be available from NNI for those who wish to continue using it.
Affordability requires long-term reform
While we will continue to do what we can to help address affordability challenges in the short-term, changes within the system are required to make sustainable and meaningful affordability a reality. What a patient pays for medicine is influenced by insurance benefit design and pricing. While Novo Nordisk has acknowledged the role of list price, more needs to be done to improve how insurance benefits cover vital medicines, especially through high deductible health plans. Those plans push list prices to patients to fulfill a deductible, which sometimes means paying thousands of dollars.
The US Internal Revenue Service (IRS) recently designated insulin as a preventive medicine. This allows high deductible health plans to cover insulin immediately, so patients only have to pay a co-pay versus requiring patients to pay list price until their deductible is met. That must be adopted by health plans – it's not automatic – and Novo Nordisk is encouraging its payer customers to adopt this rule.
"People with diabetes need more affordable options and we are going to continue doing what we can now while also working with other healthcare stakeholders on longer-term system reform. For instance, we support the recent IRS ruling that classifies diabetes medications as preventive care. We believe this has the potential to help a significant number of people with diabetes from an affordability perspective," said Doug Langa, executive vice president, North America Operations and president of Novo Nordisk Inc.
"We also want to do more to make people aware of all the programs and options across Novo Nordisk companies that may benefit them and are continuously working to ensure they are easier to access and navigate. We know that people have different challenges depending on their situation and encourage them to contact us to learn how we may be able to help," said Langa.
Affordability options already in place
The new options build upon programs Novo Nordisk already offers including:
To learn more about Novo Nordisk affordability options, visit NovoCare.com or call 1.800.727.6500.
About Novo Nordisk:
Novo Nordisk, a global healthcare company based in Denmark, has been committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, think long term and do business in a financially, socially and environmentally responsible way. In the US, Novo Nordisk employs nearly 6,000 people across affiliate companies and production and research facilities in six states.
About Novo Nordisk Inc. (NNI):
NNI is a US affiliate of Novo Nordisk. The company is based in Plainsboro, NJ and is responsible for commercialization of Novo Nordisk brands in the US and management of clinical trials in the US. For more information, visit novonordisk.us, Facebook, Instagram and Twitter.
About Novo Nordisk Pharma Inc. (NNPI):
Novo Nordisk Pharma Inc. (NNPI) is a newly established US affiliate of Novo Nordisk that is also based in Plainsboro, NJ. The company was formed in March 2019 to bring follow-on brands of Novo Nordisk branded insulin products at a reduced list price for people facing affordability challenges.
IMPORTANT SAFETY INFORMATION: Insulin Aspart
Indications and Usage
What is insulin aspart injection?
Important Safety Information
Do not share your insulin aspart FlexPen®, insulin aspart FlexTouch®, PenFill® cartridge or PenFill® cartridge compatible insulin delivery device with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Who should not take insulin aspart?
Do not take insulin aspart if:
Before taking insulin aspart, tell your health care provider about all your medical conditions including, if you are:
Talk to your health care provider about how to manage low blood sugar.
How should I take insulin aspart?
What should I avoid while taking insulin aspart?
What are the possible side effects of insulin aspart?
Serious side effects can lead to death, including:
Low blood sugar. Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please See Prescribing Information for Insulin Aspart, at https://www.novo-pi.com/insulinaspart.pdf
IMPORTANT SAFETY INFORMATION: Insulin Aspart Mix 70/30
Indications and Usage
What is insulin aspart protamine and insulin aspart injectable suspension?
Important Safety Information
Do not share your insulin aspart protamine and insulin aspart FlexPen® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Who should not use insulin aspart protamine and insulin aspart?
Before taking insulin aspart protamine and insulin aspart, tell your healthcare provider about all your medical conditions including, if you are:
Talk to your health care provider about how to manage low blood sugar.
How should I take insulin aspart protamine and insulin aspart?
What should I avoid while taking insulin aspart protamine and insulin aspart?
What are the possible side effects of insulin aspart protamine and insulin aspart?
Serious side effects can lead to death, including:
Low blood sugar. Some signs and symptoms include:
Your insulin dose may need to change because of:
Other common side effects may include:
Get emergency medical help if you have:
Please See Prescribing Information for Insulin Aspart Mix 70/30, at https://www.novo-pi.com/insulinaspartmix.pdf
SOURCE Novo Nordisk Inc. and Novo Nordisk Pharma Inc.